HELX P&L Curve
Franklin Genomic Advancements ETF (HELX) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $34.0M, listed on CBOE, carrying a beta of 0.98 to the broader market. This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. public since 2020-02-27.
A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.
- Exchange
- CBOE
- Sector
- Financial Services
- Industry
- Asset Management
- Market Cap
- $34.0M
- IPO Date
- 2020-02-27
- Beta
- 0.98
As of Nov 13, 2026, the Franklin Genomic Advancements ETF spot price is $42.01; P&L scenarios can be constructed from the options chain. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.